greeksoup/ stock research
Stock research / United States / SNY / Year to 31 December 2025

Sanofi (SNY) annual results, year to 31 December 2025: revenue EUR 43,626 million, from the 20-F

Sanofi files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue from the sale of goods of EUR 43,626 million ($49.3 billion at the year's average rate), up 6.2% on the year before. Its profit attributable to shareholders was EUR 7,813 million, up 40.5%, and diluted earnings per share EUR 6.37.

Revenue
EUR 43,626 million
+6.2% on the year
FY2018FY2025
Operating margin
14.5%
17.7% a year earlier
FY2018FY2025
Net income
EUR 7,813 million
+40.5% on the year
FY2018FY2025
Diluted EPS
EUR 6.37
+43.8% on the year
FY2018FY2025

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2024Dec 2025
Revenue from the sale of goods41,08143,626
Cost of sales13,20513,049
Gross profit31,08133,667
Research and development7,3947,842
Selling, general and administrative9,1839,543
Operating profit7,2526,344
Finance costs1,073563
Income tax1,2041,043
Profit for the year5,6187,851
Profit attributable to shareholders5,5607,813
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2024Dec 2025
Diluted EPS4.436.37
Basic EPS4.446.40
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2024Dec 2025
Cash from operations9,08110,750
Cash from investing-4,407-2,447
Cash from financing-5,763-8,207
Buybacks3025,030
Dividends paid4,7044,772
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2024Dec 2025
Funded by
Equity attributable to shareholders77,50771,376
Non-controlling interests350334
Borrowings, as filed16,13718,702
Lease liabilities1,9061,739
Other liabilities36,89834,654
Total equity and liabilities132,798126,805
Owned
Property, plant and equipment10,09110,052
Goodwill43,38441,300
Other intangible assets22,62926,261
Cash and cash equivalents7,4417,657
Inventories9,43110,214
Other assets39,82231,321
Total assets132,798126,805
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2024Dec 2025
Return on year-end equity7.2%10.9%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2025, filed 17 February 2026: the filing. The figures are in euros as filed.